Archive for the ‘HST Global Inc. HSTC’ Category

HST Global, Inc. (HSTC.OB) Announces Initiative to Target Native Americans

Friday, April 3rd, 2009

This morning, HST Global, Inc. announced that EBITDA Capital, LLC has launched an initiative, on behalf of the company, to place health and wellness center operations within the Native American Community. HST Global has asked EBITDA Capital to negotiate with known contacts within the Native American community so that health and wellness centers can be built on tribal reservations.

According to the press release, HST is focused on expanding around the world to insure that its treatments and solutions are available to all communities. The company believes the Native American communities are advantageously positioned for accessibility to both Native and Non-Native American people.

Mr. Chet Noblett, Managing General Partner that is assisting with this initiative and has a strategic plan in process, said, “We are currently working with several Native American nations and they have been very receptive to the HST Global proposals. Native Americans have always believed in the concept of being healers.”

Mr. David Martinez added, “Native Americans wish to be in a position to partner with HST Global to offer an alternative health and wellness solution. By placing these clinics on tribal lands, the opportunity for an immediate influence is enhanced for both the Native Americans and the community at large.

Ron Howell, President and CEO of HST Global, Inc. commented, “HSTC is excited to have the opportunity to leverage the contacts EBITDA Capital has within the Native American communities in developing relationships for the opening of our health and wellness centers. The opening of clinics on tribal reservations is part of the natural progression of our strategic plan to have health and wellness clinics worldwide that offer homeopathic and alternative health care options for those who are experiencing life-threatening illnesses.”

Let us hear your thoughts below:

HST Global, Inc. (HSTC.OB) Begins Saudi Arabian Project with EBITDA Capital, LLC

Thursday, February 12th, 2009

HST Global, Inc., an integrated biotechnology health and wellness company, announced today that it has commenced a project with EBITDA Capital, LLC for both shareholder participation and health and wellness center operations within Saudi Arabia.

EBITDA Capital, LLC will begin working with their contacts and clients within the Kingdom of Saudi Arabia. Key clientele within the Royal Family have shown interest in becoming shareholders in HSTC. They are also interested in operating a health and wellness clinic based within the Gulf Cooperation Council Countries (GCC). If one (or several) were to be built, they would include both for-profit and non-profit treatment facilities in support of HSTC’s late stage cancer applications. The company would be responsible for the training, maintenance and management development in these clinics.

Mr. Chet Noblett, Managing General Partner of EBITDA, is facilitating the initial negotiations and is leveraging his long term relationships with these parties. Mr. Noblett stated, “We have been cautiously opening the window of opportunity for HSTC with our associates in Saudi Arabia. Health care is a top priority throughout the GCC and HSTC offers the opportunity to energize the effort by establishing these clinics. We are very pleased to have the level of interest and acceptance that has been expressed at this time.”

Ron Howell, President and CEO of HST Global, Inc., commented, “The commencement of this initiative within the GCC Countries characterizes the essence of what HSTC is developing. The combined capital and strategic operational partnership will bring an affordable, yet cost effective treatment for late stage cancer to the GCC. HSTC is reaching across the Globe with its brand of alternative health and wellness centers.”

HSTC also told investors that it has plans to establish clinics modeled after the GCC project within a number of Asian markets where EBITDA has already made initial contacts.

Let us hear your thoughts: HST Global, Inc. Message Board

HST Global, Inc. (HSTC.OB) Announces Medical Reimbursement Initiative

Wednesday, February 4th, 2009

HST Global, Inc., an integrated biotechnology health and wellness company, announced this morning that it has launched an initiative with EBITDA Capital, LLC to pursue medical reimbursements for its treatments.

HST Global, Inc. has launched this new initiative in view of the recent changes made to the federally funded Medicare Programs. The Company has asked EBITDA Capital, LLC and its Political Affiliates to initiate a dialogue with the proper federal agencies so that their treatments for fourth stage cancer are included in Medicare payment schedules.

Mr. Chet Noblett, Managing General Partner, and his team at EBITDA Capital have already established a plan of action for contacting the government agencies. Mr. Noblett stated, “The entire Federal program for medical reimbursement is being reviewed and the cost savings from HST treatments should be considered by the appropriate agencies. Not only does HST offer a credible treatment solution but the savings to taxpayers are extremely important at this time.”

Ron Howell, President and CEO of HST Global, Inc. commented, “As I have stated previously, there is a growing population of individuals experiencing the lack of available alternatives in treating late stage cancer. In addition, the costs of these traditional alternatives have sky-rocketed over the past few years. HST is reaching across many opportunities to insure that its treatments and solutions are well recognized as not only affordable but also cost effective.”

Let us hear your thoughts: HST Global, Inc. Message Board

HST Global, Inc. (HSTC.OB) Operates in a Recession Proof Industry

Friday, January 16th, 2009

Due to the dreadful nature of cancer, HST Global, Inc. is not as affected by turbulent economic conditions. The Company’s intent is to provide World-Class treatment of cancer, as well as other life threatening diseases, regardless of the world’s economy.

During the past month, HSTC.OB has been trading around $2.00. According to Small Cap Insider’s Report, the trading action is very reminiscent of a company called Health South (HLS). HLS spent most of its life on the pink sheet market in the same range, and now trades on the NYSE near $11.00.

Let us hear your thoughts: HST Global, Inc. Message Board

HST Global, Inc. (HSTC.OB) has Established a Strategic Plan for Profitable Growth

Friday, January 16th, 2009

The growing acceptance and demand for alternative cancer treatments around the world has perfectly positioned HST Global to launch its own brand of Cancer Treatment Centers. While the company continues to look for in-licensing pre-clinical drug candidates, this strategy will enable company to address the challenges individuals face in the treatment of cancer in the later stages.

There is a growing population of individuals that are suffering as a result of the lack of available alternatives in treating late stage cancer. HST Global, Inc. has been working with a number of highly visible physicians that are developing and have developed successful protocols in the treatment of this population.

The company plans to begin opening a privately branded chain of Cancer Treatment Centers tactically positioned around the world. The distribution channel established through these Cancer Treatment Centers will serve as a platform for implementing existing technologies as well as new and emerging drug candidates as they become available.

Let us hear your thoughts: HST Global, Inc. Message Board

Keep HST Global, Inc. (HSTC.OB) on Your Radar!

Friday, January 16th, 2009

HST Global, Inc. is a development-stage biotechnology company committed to acquiring, developing and commercializing innovative products to enhance cancer care. The company determines to acquire proprietary rights to these products, fund their R&D, and bring the products to market. Since HST’s inception, they have focused their efforts and resources primarily on Salicinium, a clinical stage drug candidate, as well as raising capital and recruiting personnel.

The company’s focus is on in-licensing and further advancing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer. Although the cost of licensing drug candidates that have already completed initial clinical testing is significantly greater than those that clinical testing has not been completed, HST believes there is significantly less risk associated with the investment and continued development of clinical stage drugs since they are able to obtain an initial indication of the drug’s safety and efficacy before investing capital for the drug’s development.

HST utilizes a unique core concept in clinical drug development. Unlike many other pharmaceutical and biotech companies worldwide, HST is one of the few companies working to establish relationships and partnerships for the development of prescription drugs from natural sources to address current and emerging health crises.

HST holds to the belief that the synergy among the parts of a plant or substance from another natural source has significant value. These synergies are possibly one reason for the positive outcomes the company has encountered in pre-clinical and clinical investigations. HST takes this approach because they believe that plant co-factors, instead of a single chemical entity, will increase the overall safety and efficacy of the medicines that will potentially be produced through their efforts.

Let us hear your thoughts: HST Global, Inc. Message Board

HST Global, Inc. (HSTC.OB) is Making Great Progress with Treatment of Stage IV Breast Cancer

Monday, January 5th, 2009

In 2008, HST Global, Inc. announced that it has met 72% efficacy in pre-clinical treatment of Stage IV cancer in a test of 250 patients. In the press release announcing results, Ronald Howell, President & CEO of HST Global, Inc., stated, “We are encouraged by these results and are looking forward to subjecting the study to more rigorous tests to support eventual commercialization.”

The company has obtained the rights to a pre-clinical outcome-based study using the pre-clinical drug trade named “Salicinium”. This natural substance derived from plants is both an oral and a parenteral active inhibitor of certain fermenting enzyme dynamics in the cancer cells. Clinical studies show that Salicinium alters malignant cell fermentation dynamics, blocks cell division (mitosis), and causes fermenting cancer cells to lose their ability to endure innate immune reactions.

The pre-clinical study proved Salicinium’s efficacy and safety, as well as freedom from adverse toxicities and adverse side-effects. The study concluded that Salicinium is a novel, homeopathic, immune boosting therapy that when used alone in breast cancer, isolated from other cancers, showed an overall response rate of 79% at 33 months.

Let us hear your thoughts: HST Global, Inc. Message Board

HST Global, Inc. (HSTC.OB) and EBITDA Capital are Focused on Attaining Success Together through Strategic Alliance

Monday, December 29th, 2008

Earlier this year, HST Global announced that it contracted EBITDA Capital LLC of Newport Beach California and its group of associates to join HST-Global’s efforts in working toward an overall corporate strategy. The company also announced Former United States Congressman Bill Sarpalius, the President and CEO of Advantage Associates International, has been given the role of interfacing with the political community in Washington DC.

Mr. Sarpalius said, “We are excited to be in a position to raise the awareness of both the public and members of the government about HST’s treatment solution. The opportunity of bringing a treatment for late stage cancer is something which we all want to see expanded and made use of in the treatment community.”

Mr. Ron Howell, CEO and President of HST Global commented, “Through the use of the EBITDA Capital resources we at HST Global can focus on the issue of bringing awareness of our treatment and solution for late stage cancer treatment. We want to insure that our treatment is being given every opportunity to be recognized as the medical solution alternative of choice.”

“HST has worked to develop a complete strategy for the success of its program and treatment and is now moving toward a more public awareness platform. We believe that EBITDA and its associates, such as Advantage Associates, will help us get this done,” he continued.

Let us hear your thoughts: HST Global, Inc. Message Board

HST Global, Inc. (HSTC.OB) has Big Plans for Next year

Tuesday, December 23rd, 2008

Alternative cancer treatments have been growing in acceptance worldwide, positioning HST Global perfectly to launch a wholly owned division focused on opening a new brand of Cancer Treatment Centers. While HST Global continues to look for in-licensing pre-clinical drug candidates, this strategy will allow the company to meet the needs of individuals that face cancer treatments.

Ronald Howell, President and CEO of HST Global, Inc. stated earlier in a press release, “There is a growing population of individuals experiencing the lack of available alternatives in treating late stage cancer. We have been working with a number of highly visible Physicians that are and have developed successful protocols that are meeting with success in the treatment of this population. As such, we will begin opening a privately branded chain of Cancer Treatment Centers strategically positioned around the world through a new wholly owned subsidiary.”

Mr. Howell continued, “The distribution channel established through our Cancer Treatment Centers will serve as a platform for implementing existing technologies and serve to identify appropriate communities for treatment with new and emerging drug candidates as they become available.”

Cancer is a world epidemic that does not discriminate. HST Global, Inc. has been involved with pre-clinical and proven drug candidates that have demonstrated high efficacy in the treatment of various cancers. The success and high efficacy recognized in these treatments has attracted a number of International partners that want to join the company’s vision and open Centers worldwide. Establishing a global chain of Cancer Treatment Centers will provide an immediate revenue stream to the company.

HST Global believes a number of events will take place in the coming year based on negotiations that have taken place. The Company intends to open its first corporate owned center in the first quarter 2009 and five partner centers worldwide in fiscal 2009. The annual estimated revenue stream from each individual clinic is estimated to be approximately $8-10 million dollars per year.

The Company will continue to search for revolutionary and novel products for the treatment of cancer and other life threatening diseases. Because of the unfortunate nature of cancer, the Company does not believe it will be affected by current or future economic conditions.

Let us hear your thoughts: HST Global, Inc. Message Board

HST Global, Inc. (HSTC.OB) Strengthens Scientific Board with New Member

Friday, December 19th, 2008

HST Global, Inc. announced earlier this month that Dr. Kyl Smith has joined its Scientific Board. Much of Dr. Smith’s visibility has been earned in the world of natural medicine. He is a noted researcher, inventor, lecturer, author and scientist, and is known as the inventor of Focus Factor®, the number-one selling brain support product in North America for the last seven years.

Dr. Kyl’s passion is teaching doctors how to use nutritional therapies to improve cognitive function. He has been featured on numerous radio and television programs across the country, is the author of the acclaimed Brighter Mind® book series and is a popular speaker providing Continuing Education programs for physicians.

With the help of a team of top scientists, Dr. Kyl filed a Health Claim Petition for Phosphatidylserine, which was approved by the Food and Drug Administration (FDA) in 2002. This is an unprecedented achievement represents the first Health Claim for cognitive function to be approved in the FDA’s history.

Ronald Howell, President and CEO of HST Global, Inc. stated, “There is a growing acceptance of integrative wellness and cancer treatments worldwide and HST is perfectly positioned to open our own brand of Integrative Wellness and Cancer Treatment Centers.”

Commenting on the announcement, Mr. Howell continued, “The addition of Dr. Kyl Smith to our Scientific Advisory Board will enable the company to strengthen our ability to address multiple challenges individuals face in the maintenance and treatment of numerous health conditions, and to provide Continuing Education modules and courses for physicians who wish to learn about scientifically validated integrative therapies.”

Let us hear your thoughts: HST Global, Inc. Message Board

HST Global, Inc. (HSTC.OB) is “One to Watch”

Thursday, December 18th, 2008

HST Global, Inc. is a development-stage biotechnology company committed to acquiring, developing and commercializing innovative products to enhance cancer care. The company determines to acquire proprietary rights to these products, fund their R&D, and bring the products to market. Since HST’s inception, they have focused their efforts and resources primarily on Salicinium, a clinical stage drug candidate, as well as raising capital and recruiting personnel.

The company’s focus is on in-licensing and further advancing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer. Although the cost of licensing drug candidates that have already completed initial clinical testing is significantly greater than those that clinical testing has not been completed, HST believes there is significantly less risk associated with the investment and continued development of clinical stage drugs since they are able to obtain an initial indication of the drug’s safety and efficacy before investing capital for the drug’s development.

HST utilizes a unique core concept in clinical drug development. Unlike many other pharmaceutical and biotech companies worldwide, HST is one of the few companies working to establish relationships and partnerships for the development of prescription drugs from natural sources to address current and emerging health crises.

HST holds to the belief that the synergy among the parts of a plant or substance from another natural source has significant value. These synergies are possibly one reason for the positive outcomes the company has encountered in pre-clinical and clinical investigations. HST takes this approach because they believe that plant co-factors, instead of a single chemical entity, will increase the overall safety and efficacy of the medicines that will potentially be produced through their efforts.

Let us hear your thoughts: HST Global, Inc. Message Board